- Home
- BLDE vs VNDA Comparison
BLDE vs VNDA Comparison
Compare BLDE & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLDE
- VNDA
- Stock Information
- Founded
- BLDE 2014
- VNDA 2002
- Country
- BLDE United States
- VNDA United States
- Employees
- BLDE N/A
- VNDA N/A
- Industry
- BLDE Aerospace
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- BLDE Consumer Discretionary
- VNDA Health Care
- Exchange
- BLDE Nasdaq
- VNDA Nasdaq
- Market Cap
- BLDE 215.1M
- VNDA 237.9M
- IPO Year
- BLDE N/A
- VNDA 2006
- Fundamental
- Price
- BLDE $3.45
- VNDA $3.98
- Analyst Decision
- BLDE Strong Buy
- VNDA Strong Buy
- Analyst Count
- BLDE 2
- VNDA 2
- Target Price
- BLDE $6.25
- VNDA $16.50
- AVG Volume (30 Days)
- BLDE 565.2K
- VNDA 477.8K
- Earning Date
- BLDE 05-12-2025
- VNDA 05-07-2025
- Dividend Yield
- BLDE N/A
- VNDA N/A
- EPS Growth
- BLDE N/A
- VNDA N/A
- EPS
- BLDE N/A
- VNDA N/A
- Revenue
- BLDE $251,485,000.00
- VNDA $201,351,000.00
- Revenue This Year
- BLDE $5.13
- VNDA $14.36
- Revenue Next Year
- BLDE $8.63
- VNDA $44.53
- P/E Ratio
- BLDE N/A
- VNDA N/A
- Revenue Growth
- BLDE 8.67
- VNDA 13.37
- 52 Week Low
- BLDE $2.35
- VNDA $3.85
- 52 Week High
- BLDE $5.17
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- BLDE 70.73
- VNDA 35.66
- Support Level
- BLDE $2.73
- VNDA $3.94
- Resistance Level
- BLDE $2.99
- VNDA $4.51
- Average True Range (ATR)
- BLDE 0.15
- VNDA 0.17
- MACD
- BLDE 0.09
- VNDA -0.04
- Stochastic Oscillator
- BLDE 82.24
- VNDA 9.59
About BLDE Blade Air Mobility Inc.
Blade Air Mobility Inc is a technology-powered air mobility platform that provides air transportation and logistics for hospitals and is a transporter of human organs for transplant, and for passengers, with helicopter and fixed-wing services predominantly in the Northeast United States, Southern Europe and Western Canada. The company's operating segments are; Passenger, and Medical. Majority of the revenue for the company is generated from its Medical segment which predominantly consists of transportation of human organs for transplant and the medical teams supporting these services. It also offers additional services including donor logistics coordination and support in evaluating potential donor organs. A substantial portion of the company's revenue is generated from the United States.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.